PRS: Myeloma & MDS Physician InformationPRS: Myeloma & MDS Advisory BoardPRS: Myeloma & MDS Confidentiality Statement
NewslettersPRS: Myeloma & MDS Related LinksPRS: Myeloma & MDS Contact UsPRS:Myeloma Patient WebsitePRS:MDS Patient WebsiteSlone Epidemiology Center Website

Information for Physicians

The Slone Epidemiology Center at Boston University is enrolling patients who have been recently diagnosed with multiple myeloma or myelodysplastic syndrome (MDS) in a voluntary research project called Patient Registries at Slone: Myeloma and MDS. These registries gather information on the clinical, economic, and quality of life outcomes experienced by patients on both established treatments (including observation or supportive care) and new modalities. The registry for each disease will enroll patients soon after diagnosis and follow them indefinitely.

Since treatment for these diseases is developing rapidly, it is important to obtain systematic information on the wide range of outcomes experienced by patients outside of the context of randomized clinical trials, which frequently are conducted in highly selected populations for relatively short periods. To best assure a representative sample, the nationwide PRS: Myeloma & MDS seeks to enroll patients followed by physicians in both community settings and specialty centers. These registries will provide myeloma and MDS clinicians and researchers with generalizable outcome information that can guide both clinical decision making and future research efforts.

Due to a lack of funding, the registry is now closed. We appreciate your interest and apologize for any inconvenience. For more information, email us at

Patients’ participation is voluntary and confidential. Their names will not be shared with anyone outside the registry team. The registries are not clinical trials and patients’ participation will not affect their course of treatment.

The registries have been approved by the Boston University Institutional Review Board and are conducted with the guidance of an independent advisory board.

The registries were sponsored by Celgene Corporation with additional support from Millennium Pharmaceuticals.

To view our presentations:

To view the poster presented at the 2007 annual meeting of the American Society of Hematology (ASH), click here.

To view the poster presented at the 2008 annual meeting of the American Society of Clinical Oncology (ASCO), click here.

To view our presentations at the 2008 annual meeting of the American Society of Hematology (ASH), click here for our poster (myeloma) and click here for the slides from our oral presentation (MDS).


Last Updated: March 10, 2009